Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54 per share. Each share of common stock is accompanied by a warrant to purchase one share of common stock at an exercise price of $0.54 per share, which is immediately exercisable and will expire 18 months from the date of issuance, or a short-term warrant, and a warrant to purchase one share of common stock at an exercise price of $0.54 per share, which is immediately exercisable and will expire 5 years from the date of issuance, or a long-term warrant. The gross proceeds to Calithera from the offering are expected to be approximately $10.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock and warrants are being offered by Calithera. The offering is expected to close on April 1, 2022, subject to customary closing conditions.

Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, warrants to purchase shares of its common stock, and pre-funded warrants in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Calithera.

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

Sphere 3D

Clarus Therapeutics Holdings

Can these meme penny stocks under $3 make you money next month? The post 3 Hot Meme Penny Stocks to Watch Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Meme Penny Stocks to Watch Under $3 Right Now

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's fourth quarter and full year 2021 financial results will be released on Thursday, March 31, 2022. Company management will host a conference call on Thursday, March 31, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022

First data from preclinical synthetic lethality program of novel VPS4A inhibitors with potential for clinical advancement in variety of cancers First data from preclinical synthetic lethality program of novel VPS4A inhibitors with potential for clinical advancement in variety of cancers

Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. Eastern Time. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

The stock price of Calithera Biosciences Inc (NASDAQ: CALA) increased by 55.65% in the most recent trading session. This is why it happened.

Calithera Biosciences (CALA) Stock: Why The Price Jumped Up

MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year.

AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference.

Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?

The stock price of Calithera Biosciences Inc (NASDAQ: CALA) increased by over 20% pre-market today. This is why it happened.

Calithera Biosciences (CALA) Stock: Why The Price Jumped Today

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the 2021 Jefferies London Healthcare Conference.

Calithera to Present at the 2021 Jefferies London Healthcare Conference

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2021 Results - Earnings Call Transcript

-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of September 30, 2021 --

Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

Calithera Biosciences Inc (NASDAQ: CALA) has decided to terminate its phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. The Phase 2 KEAPSAKE study was designed to evaluate the safety and anti-tumor activity of telaglenastat plus standard-of-care chemo-immunotherapy as front-line therapy for stage IV non-squamous non-small cell lung cancer (NSCLC) harboring KEAP1 or NRF2 mutation.

Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?

-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors -- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors

Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer

--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat

Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's third quarter 2021 financial results will be released on Tuesday, November 9, 2021. Company management will host a conference call on Tuesday, November 9, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

Calithera Biosciences Inc (NASDAQ: CALA) shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company's investigational arginase inhibitor, in adults with cystic fibrosis (CF).  The data were shared at the North American Cystic Fibrosis Foundation Conference (NACFC).

Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial

-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects -- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride -- Early positive trend seen in FEV1, a safety endpoint

Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company's investigational arginase inhibitor for the treatment of cystic fibrosis (CF), will be shared in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place virtually November 2-5, 2021.

Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock.

Calithera Buys Two Oncology Candidates From Takeda For $45M

-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company's precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022 --

Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals

KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2 pathway

Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its participation in two upcoming virtual healthcare investor conferences.

News for Calithera Biosciences Stock (CALA)